GlaxoSmithKline confirmed last week that it's investigating allegations of misconduct in its Jordan and Lebanon operations, the latest in a sequence of mounting investigations across the global pharmaceutical giant.

GSK is investigating claims into whether some of its employees bribed doctors in Jordan and Lebanon by making bribery payments in the form of flexible travel arrangements, for example, in exchange for promoting and prescribing its drugs. The company is facing similar bribery probes in Poland, Iraq, and China.

“GSK can confirm we are investigating allegations regarding the activity of a small number of individuals in our operations in Jordan and Lebanon,” the company stated. “We started investigating using internal and external teams as soon as we became aware of these claims. These investigations have not yet concluded.”

GSK added that it publicly disclosed a total of 161 violations relating to breaches of its sales and marketing policies in 2013, resulting in 48 dismissals and 113 written warnings. “These numbers are very similar to those reported by other companies in our sector,” the company stated.

Despite the mounting investigations, GSK stated, “We are confident in our processes and controls and that we do not have a systemic issue with unethical behavior.”